Chemours Company (The) (CC) Shares Sold by Howard Hughes Medical Institute

Howard Hughes Medical Institute decreased its position in shares of Chemours Company (The) (NYSE:CC) by 53.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,993 shares of the specialty chemicals company’s stock after selling 34,560 shares during the period. Howard Hughes Medical Institute’s holdings in Chemours Company (The) were worth $1,137,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CC. Janney Montgomery Scott LLC acquired a new position in Chemours Company (The) during the first quarter worth approximately $296,000. Oregon Public Employees Retirement Fund acquired a new position in Chemours Company (The) during the first quarter worth approximately $568,000. Wells Fargo & Company MN increased its position in Chemours Company (The) by 21.7% during the first quarter. Wells Fargo & Company MN now owns 331,492 shares of the specialty chemicals company’s stock worth $12,762,000 after buying an additional 59,003 shares during the period. First Trust Advisors LP increased its position in Chemours Company (The) by 51.5% during the first quarter. First Trust Advisors LP now owns 163,136 shares of the specialty chemicals company’s stock worth $6,281,000 after buying an additional 55,427 shares during the period. Finally, American Century Companies Inc. acquired a new position in Chemours Company (The) during the first quarter worth approximately $6,697,000. 72.90% of the stock is currently owned by institutional investors.

In other news, VP Amy Trojanowski sold 2,500 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $46.03, for a total transaction of $115,075.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP David C. Shelton sold 13,337 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $48.48, for a total value of $646,577.76. The disclosure for this sale can be found here. Insiders have sold a total of 38,837 shares of company stock worth $1,865,603 over the last quarter. Insiders own 1.14% of the company’s stock.

Shares of Chemours Company (CC) traded up 1.41% on Friday, hitting $50.36. The company’s stock had a trading volume of 3,017,772 shares. The company has a 50 day moving average of $49.94 and a 200 day moving average of $42.84. Chemours Company has a 1-year low of $14.07 and a 1-year high of $51.59. The firm has a market cap of $9.31 billion, a PE ratio of 32.96 and a beta of 3.64.

Chemours Company (The) (NYSE:CC) last announced its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.02. The business had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The business’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.27 EPS. Equities analysts forecast that Chemours Company will post $3.51 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Thursday, August 17th were given a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.24%. The ex-dividend date was Tuesday, August 15th. Chemours Company (The)’s payout ratio is 8.11%.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/17/chemours-company-the-cc-shares-sold-by-howard-hughes-medical-institute.html.

CC has been the topic of several research analyst reports. ValuEngine raised Chemours Company (The) from a “hold” rating to a “buy” rating in a research report on Friday, June 2nd. UBS AG reaffirmed a “sell” rating and set a $36.00 price target (up previously from $35.00) on shares of Chemours Company (The) in a research report on Wednesday, June 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $48.00 price target on shares of Chemours Company (The) in a research report on Friday, June 16th. BidaskClub lowered Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Saturday, June 17th. Finally, Citigroup Inc. raised Chemours Company (The) from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $43.00 to $45.00 in a research report on Wednesday, July 5th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $51.50.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply